Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline...
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline...
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025WOODCLIFF LAKE, N.J., April 30,...
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its...
An automated outbreak detection tool reduced the size of outbreaks by 64% in the trial period preceding the COVID-19 pandemic...
Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce...
Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and...
Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a...
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health...
TYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and...
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone...
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous...
Digostics and AgaMatrix Team Up to Improve Gestational Diabetes Screening for UK Women via the Introduction of Oral Glucose Tolerance...
TAMPA, FL / ACCESSWIRE / April 4, 2024 / On April 1, 2024, the Florida State Supreme Court rendered two...
Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2%...
Phase 1a study of first hormone-free male pill completes enrollmentDURHAM, NC / ACCESSWIRE / March 27, 2024 / Male Contraceptive...
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy...
Building on GE HealthCare’s legacy in medical technology, the GE HealthCare Foundation will advance equitable access to precision healthcare with...
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as...
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high...